Business Context and Reporting Period
This Form 8-K filing by Neuralstem, Inc. (Note: Metadata listed "Palisade Bio, Inc." but the filing text identifies the registrant as Neuralstem, Inc.) covers events occurring on June 21, 2017, and June 22, 2017. The report details the results of the 2017 Annual Meeting of Stockholders and an amendment to the non-employee Board compensation policy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and compensation matters rather than financial performance.
Material Changes and Corporate Actions
Annual Meeting Results (June 22, 2017)
- Quorum: 7,180,865 shares represented out of 11,899,453 outstanding shares.
- Proposal 1 (Director Election): Richard Daly was elected as Class III Director. Votes For: 1,745,740; Votes Withheld: 23,685; Non-Votes: 5,411,440.
- Proposal 2 (Auditor Ratification): Dixon, Hughes, Goodman was ratified. Votes For: 7,029,592; Votes Against: 57,772; Abstentions: 93,501.
- Proposal 3 (Equity Plan Amendment): Approved an increase of 700,000 shares eligible for issuance under the 2010 Equity Compensation Plan. Votes For: 1,317,087; Votes Against: 412,735; Abstentions: 39,603.
- Proposal 4 (Say-on-Pay): Non-binding advisory vote on executive compensation was approved. Votes For: 1,556,672; Votes Against: 172,631; Abstentions: 40,122.
- Proposal 5 (Say-on-Frequency): Stockholders voted for a 1-year frequency (1,166,241 votes). However, the Board determined future advisory votes will occur every 3 years.
Board Compensation Amendment (Effective July 1, 2017)
- Non-employee directors will receive a $100,000 annual board fee.
- Payment structure: Up to $50,000 in cash (quarterly) and the balance in equity grants (options, RSUs, or restricted stock) at the director's election.
- Equity grants vest quarterly over the grant year.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, or specific risk factors. The primary operational change noted is the Board's decision to hold executive compensation advisory votes every 3 years, overriding the stockholder preference for annual votes.
Investor Verification Checklist
- Verify the exact number of shares authorized under the amended 2010 Equity Compensation Plan post-approval.
- Confirm the specific mix of cash versus equity elected by individual directors under the new $100,000 fee structure.
- Review the Board's rationale for selecting a 3-year frequency for say-on-pay votes despite the stockholder vote favoring a 1-year frequency.
- Check subsequent filings for the valuation assumptions used for the new equity grants (Black-Scholes inputs).